Topical treatment of actinic keratoses with potassium dobesilate 5% cream. A preliminary open-label study

European Journal of Medical Research

C Giménez-Gallego⁴  J Angulo³  C Pérez¹  W Espinoza²  P Cuevas³ 

[1]Servicio de Farmacia. Hospital Universitario Ramón y Cajal. Madrid

[2]Servicio de Dermatología. Hospital Universitario Ramón y Cajal. Madrid

[3]Departamento de Investigación. Servicio de Histología. IRYCIS. Hospital Universitario Ramón y Cajal, Madrid

[4]Departamento de Biología Fisico-Química, Centro de Investigaciones Biológicas Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain

关键词: Fibroblast growth factor;    Dobesilate;    Actinic keratosis;   

Others  :  828451
DOI  :  10.1186/2047-783X-16-2-67

 received in 2010-08-20, accepted in 2010-10-20,  发布年份 2011

【 摘 要 】

Background

Fibroblast growth factor (FGF) is involved in skin tumorigenesis: it promotes cell viability, induces angiogenesis and stimulates invasiveness. Dobesilate is a drug that blocks the activity of FGF. The primary objective was to evaluate the efficacy and tolerability of potassium dobesilate 5% cream in the treatment of actinic keratoses.

Methods

Potassium dobesilate 5% cream was applied twice daily for 16 weeks to actinic keratosis lesions in 30 patients. The lesions were evaluated clinically at an initial baseline visit, at intermediate visits, and at 16 weeks of treatment.

Results

The use of potassium dobesilate 5% cream for 16 weeks induced complete regression in 70% of evaluated actinic keratoses, corresponding to grade I, II and III clinical variants, and a partial response (at least 75% reduction of lesions) in 20% of the cases.

Conclusion

Our preliminary trial shows that potassium dobesilate exerts anti-tumorigenic effects and may play a useful role in the chemoprevention of skin cancers.

【 授权许可】

   
2011 I. Holzapfel Publishers

【 图 表 】

Figure 1.

Figure 1.

【 参考文献 】

• [1]Selasche SJ: Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000, 42:4-7.
• [2]Ackerman AB: Solar keratosis is squamous cell carcinoma. Arch Dermatol 2003, 139:1216-7.
• [3]Röwert-Huber J, Patel MJ, Forschner T, et al.: Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007, 156(Suppl 3):8-12.
• [4]Gupta AK: The management of actinic keratoses in the United States wih topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002, 70:30-6.
• [5]Lebwohl M, Dinehart S, Whiting D, et al.: Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004, 50:714-21.
• [6]Rivers JK, Arlette J, Shear N, et al.: Topical treatment of actinic keratoses with 3.0% diclofenac in 2, 5% hyaluronic gel. Br J Dermatol 2002, 146:194-200.
• [7]Campione E, Diluvio L, Paterno EJ, Chimenti S: Topical treatment of actinic keratoses with piroxicam 1% gel. A preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol 2010, 11:45-50.
• [8]Cuevas P, Arrazola JM: Treatment of basal cell carcinoma with topical dobesilate. J Am Acad Dermatol 2005, 53:526-7.
• [9]Fernandez IS, Cuevas P, Angulo J, et al.: Gentisic acid, a compound associated with plant defence and a metabolite of aspirin, heads a new class of in vivo FGF inhibitor. J Biol Chem 2010, 285:11714-29.
• [10]Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-32.
• [11]Strieth S, Hartschuh W, Pilz L, Fusening NE: Angiogenic swith occurs late in squamous cell carcinomas of human skin. Br J Cancer 2000, 82:591-600.
• [12]Wang Y, Becker D: Antisense targeting of basic fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997, 8:887-93.
• [13]Arbiser JL, Byers HR, Cohen C, Arbeits J: Altered basic fibroblast growth factor expression in common epidermal neoplasms: examination with in situ hybridization and immunohistochemistry. J Am Acad Dermatol 2000, 42:973-7.
• [14]Cuevas P, De Miguel R, Espinoza W, et al.: Antimelanoma effect of a synthetic inhibitor of fibroblast growth factor (FGF) [abstract no° 79 plus Poster]. In 13th World Congress on Cancers of the Skin. Madrid (Spain); 2010.